A Phase 3 Multicenter Study of Gleolan® (Aminolevulinic Acid Hydrochloride) to Enhance Visualization of Tumor in Patients With Suspected Newly Diagnosed or Recurrent Epithelial Ovarian Cancer
This study tests a special medication called Gleolan to help surgeons see ovarian cancer tumors more clearly during surgery. By making the cancer cells glow, it helps doctors remove as much of the tumor as possible.
You might be able to join if you have been diagnosed with, or are strongly suspected to have, ovarian cancer and are already planning to have surgery to remove it. You also need to be healthy enough for surgery with normal organ function.
You will take the Gleolan medication before your scheduled surgery, and your surgical team will use special equipment to view the glowing cancer cells. Your personal involvement with the study lasts about two weeks.
The study is currently recruiting participants at hospital locations in Phoenix, Arizona, Jacksonville, Florida, and Annapolis, Maryland. It is expected to run for about 18 months in total.
- 1Uses a glowing medication to help surgeons see cancer cells
- 2Participation lasts for about two weeks around your surgery
- 3Open to patients with ovarian cancer who are already planning surgery
Related links
Outside pages about this study, checked by our team
This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.